Ozempic, Wegovy Medicare Prices Muddled by Trump's Dueling Deals

Healthcare attorney Melissa Wong was interviewed for a Bloomberg Law article about confusion regarding prices for some GLP-1 drugs following deals the Trump Administration struck with their maker and for the second round of the Medicare Drug Price Negotiation Program. The administrated negotiated a 71 percent price reduction for Novo Nordisk's Ozempic, Wegovy and Rybelsus diabetes and obesity drugs under a most-favored nation (MFN) policy, but it later included these drugs in the list of those selected for negotiated prices with the Centers for Medicare and Medicaid Services (CMS) under the maximum fair price (MFP) process. The prices agreed upon with Novo Nordisk take effect in 2026, whereas the prices determined with CMS take effect in 2027; in the meantime, the insurance and pharmaceutical industries await guidance on how much the drugs will cost and how the deals will interact with each other.

"The negotiated price for Ozempic and Wegovy merits the most attention because it is unclear how this will work in light of the deal that the Trump Administration struck earlier this month with Novo Nordisk," Ms. Wong commented.

READ: Ozempic, Wegovy Medicare Prices Muddled by Trump's Dueling Deals